News
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,
In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...
Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback